SELLAS Life Sciences Group, Inc.
SLS evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $2.72B
- Lead Asset:
- gps+ (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLS
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company developing a dual-platform oncology pipeline focused on acute myeloid leukemia (AML), with its lead candidate GPS in a Phase 3 REGAL trial and SLS009, a CDK9 inhibitor, advancing through Phase 2 studies.
Key risk: Binary REGAL outcome
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.72B
Cash Runway
—
Lead Asset
gps+ (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for SELLAS Life Sciences Group, Inc..
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company developing a dual-platform oncology pipeline focused on acute myeloid leukemia (AML), with its lead candidate GPS in a Phase 3 REGAL trial and SLS009, a CDK9 inhibitor, advancing through Phase 2 studies.
- Lead candidate GPS (galinpepimut-S) is a peptide immunotherapy targeting the WT1 antigen, currently in a Phase 3 REGAL trial for AML [pipeline].
- SLS009, a CDK9 inhibitor, has shown preclinical activity in MYC-amplified, RAS inhibitor-resistant pancreatic cancer organoid models [news · published 2026-10-01].
- Cash and equivalents were $138.3M as of 2026-06-30 [sec].
- Net loss for the first quarter of 2026 was $8.41 million, with a narrowed basic loss per share of $0.05 [news · published 2026-05-15].
- The REGAL trial had reached 78 of 80 events needed for final analysis as of May 2026 [news · published 2026-05-15].
What works
- Cash position of $138.3M as of 2026-06-30 provides a multi-year runway to advance pipeline milestones [sec].
- GPS is in a pivotal Phase 3 REGAL trial nearing final analysis (78 of 80 events reached), representing a near-term catalyst [news · published 2026-05-15].
- SLS009 has generated positive Phase 2 data in relapsed/refractory AML, accepted for presentation at ASH 2025, and is expanding into newly diagnosed first-line AML [news · published 2025-11-12].
- Preclinical data for SLS009 in pancreatic cancer models suggests potential to address RAS inhibitor resistance, broadening the pipeline beyond AML [news · published 2026-10-01].
What to weigh
- The company reported a net loss of $8.41 million in Q1 2026, indicating ongoing operating losses [news · published 2026-05-15].
- Stock valuation has been flagged as expensive despite clinical progress, with a 3-year return of about 7.9x setting a high bar for further upside [news · published 2026-08-21].
- The REGAL trial is event-driven, and the binary outcome (success or failure) introduces significant binary risk for the GPS program [news · published 2026-07-14].
- SLS009 is still in early-to-mid-stage clinical development (Phase 2), with no approved product revenue yet [news · published 2026-05-15].
From the filings
Quoted directly from source documents.
GPS is in Phase 3 for AML
“Pipeline Candidate: galinpepimut-s Generic Name: GPS Indication: Acute Myeloid Leukemia Phase: Phase 3”
REGAL trial at 78 of 80 events
“its pivotal Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis”
News · May 15, 2026
SLS009 preclinical data in pancreatic cancer
“its CDK9 inhibitor SLS009 induced meaningful cancer cell death in MYC-amplified, daraxonrasib-resistant pancreatic ductal adenocarcinoma organoid models”
News · October 1, 2026
Catalyst timeline
- 2021-02-08 · Phase 3 REGAL trial start — A randomized, open-label study of GPS maintenance monotherapy vs. investigator's choice in AML patients who achieved complete remission after second-line salvage therapy.
Risks & what to watch (4)›
Key risks
- Binary REGAL outcome — The Phase 3 REGAL trial is event-driven; a negative result would severely impact GPS's prospects [news · published 2026-07-14].
- No approved products — SELLAS has no marketed products; all revenue depends on clinical success and regulatory approval [pipeline].
- Valuation overhang — Stock is flagged as expensive after a 7.9x 3-year return, limiting perceived upside [news · published 2026-08-21].
- Ongoing net losses — Q1 2026 net loss of $8.41M shows continued cash burn despite strong cash position [news · published 2026-05-15].
What to watch
- Final analysis readout of the Phase 3 REGAL trial for GPS in AML [news · published 2026-05-15].
- Initiation of the Phase 2 trial for SLS009 in newly diagnosed first-line AML, expected Q1 2026 [news · published 2025-11-12].
- Further preclinical or clinical data for SLS009 in pancreatic cancer and other solid tumors [news · published 2026-10-01].
- Cash runway management and any additional financing or partnership deals [news · published 2026-08-02].
Sources: Catalysts · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run SELLAS Life Sciences Group, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SELLAS Life Sciences Group, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
159
Total value held
$224.6M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,198,410 | $51.6M |
| state street corp | 8,396,356 | $35.5M |
| vanguard capital management llc | 7,525,929 | $31.8M |
| geode capital management, llc | 3,912,606 | $16.6M |
| marshall wace, llp | 2,037,162 | $8.6M |
| jones financial companies lllp | 1,675,077 | $7.3M |
| vanguard portfolio management llc | 1,462,806 | $6.2M |
| morgan stanley | 1,336,293 | $5.7M |
| northern trust corp | 1,275,984 | $5.4M |
| vanguard fiduciary trust co | 1,202,839 | $5.1M |
Showing top 10 of 159 institutional holders of SELLAS Life Sciences Group, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 30.0%
- Days to cover
- 6.5
- Shares short
- 53,525,042
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLS short interestGovernance
Frequently asked questions
What is the AI investment thesis for SELLAS Life Sciences Group, Inc.?
SELLAS Life Sciences Group, Inc. (SLS) is a clinical-stage biopharmaceutical company developing a dual-platform oncology pipeline focused on acute myeloid leukemia (AML), with its lead candidate GPS in a Phase 3 REGAL trial and SLS009, a CDK9 inhibitor, advancing through Phase 2 studies.
What is SELLAS Life Sciences Group, Inc.'s lead drug candidate?
SELLAS Life Sciences Group, Inc.'s most advanced tracked candidate is gps+ (Phase 3) for Cancer.
Who is the CEO of SELLAS Life Sciences Group, Inc.?
Dr. Angelos M. Stergiou M.D., ScD h.c. is the chief executive officer of SELLAS Life Sciences Group, Inc. (SLS).
Where is SELLAS Life Sciences Group, Inc. headquartered?
SELLAS Life Sciences Group, Inc. (SLS) is headquartered in New York, NY, United States.
What therapeutic areas does SELLAS Life Sciences Group, Inc. focus on?
SELLAS Life Sciences Group, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.